ArticleBone marrow research2011
Signaling proteins and transcription factors in normal and malignant early B cell development.
Article in Bone marrow research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.Blood advances · 2026Article
- Inflammation as a driver of hematological malignancies.Frontiers in oncology · 2024Review
- Cell-cell interactome of the hematopoietic niche and its changes in acute myeloid leukemia.iScience · 2023Article
- Extracellular vesicle small RNA cargo discriminates non-cancer donors from pediatric B-lymphoblastic leukemia patients.Frontiers in oncology · 2023Article
- Thyroid Hormone Receptor α1 Mutants Impair B Lymphocyte Development in a Mouse Model.Thyroid : official journal of the American Thyroid Association · 2021Article
- Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.Oncology letters · 2021Review
- Review
- ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies.BioMed research international · 2015Review
- Genome-wide DNA methylation analysis in precursor B-cells.Epigenetics · 2014Article
- TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer.Cancer research · 2014Article
- B cell lymphoma in HIV transgenic mice.Retrovirology · 2013Article
- Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle.PloS one · 2013Article
- Lymphoid progenitor cells from childhood acute lymphoblastic leukemia are functionally deficient and express high levels of the transcriptional repressor Gfi-1.Clinical & developmental immunology · 2013Article
- TLR stimulation of bone marrow lymphoid precursors from childhood acute leukemia modifies their differentiation potentials.BioMed research international · 2013Article
- MicroRNAs in B cell development and malignancy.Journal of hematology & oncology · 2012Review
- Lineage switching in acute leukemias: a consequence of stem cell plasticity?Bone marrow research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cell development starts in bone marrow with the commitment of hematopoietic progenitors to the B cell lineage. In murine models, the IL-7 and preBCR receptors, and the signaling pathways and transcription factors that they regulate, control commitment and maintenance along the B cell pathway. E2A, EBF1, PAX5, and Ikaros are among the most important transcription factors controlling early development and thereby conditioning mice homeostatic B cell lymphopoiesis. Importantly, their gain or loss of function often results in malignant development in humans, supporting conserved roles for these transcription factors. B cell acute lymphoblastic leukemia is the most common cause of pediatric cancer, and it is characterized by unpaired early B cell development resulting from genetic lesions in these critical signaling pathways and transcription factors. Fine mapping of these genetic abnormalities is allowing more specific treatments, more accurately predicting risk profiles for this disease, and improving survival rates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.